View Post

Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

In Clinical Trials by Barbara Jacoby

From: apnews.com Dec 8, 2018–Generon BioMed Holding Ltd. (Generon), announced today at the annual San Antonio Breast Cancer Symposium (SABCS), positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein, designed using Generon’s Dikine TM technology platform. Led by Principle Investigator Dr. John Glaspy, Estelle, Abe and Marjorie Endowed Chair in Cancer Research …

View Post

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment

In In The News by Barbara Jacoby

From: biospace.com Agendia, Inc., a world leader in precision oncology, announced today findings from two key studies presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) this week, reinforcing the utility and benefits of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence and BluePrint® Breast Cancer Molecular Subtyping tests. Both studies underscore the growing importance of genomic testing in helping physicians …

View Post

New medicine reduces the risk of breast cancer recurring by 50 percent, researchers say

In In The News by Barbara Jacoby

By: Reba Hollingsworth From: wtvr.com Thirty-eight-year-old Ticiana Machado is going through her second round of chemotherapy. The wife and mother of two was diagnosed with breast cancer two months ago. “How you doing? How you feeling?” said Dr. Mary Helen Hackney. Ticiana’s doctor Mary Helen Hackney with VCU Massey Cancer Center says a new drug combo may help patients like …

View Post

Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

In In The News by Barbara Jacoby

From: businesswire.com Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update Biotheranostics, Inc. announces recommendations for Breast Cancer Index …

View Post

2 Trials, Now Enrolling, Aimed at Improving Breast Cancer Prevention, Diagnosis, and Treatment

In Clinical Trials by Barbara Jacoby

By: Patricia Inacio, PhD From: breastcancer-news.com The University of Hawaiʻi Cancer Center is enrolling participants in two clinical trials to test new ways of preventing and diagnosing breast cancer, as well as improving current treatments. “These trials are very important because breast cancer is a significant issue in Hawaiʻi,” Randall Holcombe, director of the UH Cancer Center said in a press release. “Racial and ethnic minority …

View Post

Breast cancer: Tumor growth fueled by bone marrow cells

In In The News by Barbara Jacoby

By: Ana Sandoiu From: medicalnewstoday.com New research, published in the Journal of Experimental Medicine, reveals a novel mechanism that fuels tumor growth in breast cancer and may have a negative impact on a person’s outlook. However, the findings might also help scientists develop individually tailored treatments that target breast cancer tumors more precisely. Neta Erez, a senior lecturer in the …

View Post

uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.

In In The News by Barbara Jacoby

From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said …